Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Tim Cruise who wrote (95)	3/4/1999 11:17:00 AM
From: thebeach	Read Replies (1) \| Respond to of 356

Great site,we are going to be better than that.Also,by the looks of the bid and ask someone is positioning for an assault on the buy side. Currently they are trying to shake the weak hands.Forget it guys,we are not selling. Wait a minute,just pulled this off the newswire: James Youmans Joins Procyon BioPharma's Board of Directors LONDON, ON, March 3 /CNW/ - Procyon BioPharma Inc. (ASE: PBP) announced today the election of James C. Youmans to the Company's Board of Directors. Mr. Youmans was formerly Head, Global Marketing and Country Operations of Novartis Pharma AG based in Basel, Switzerland. His responsibilities included strategic development and implementation as well as new product introductions. ''I am delighted to welcome Mr. Youmans to our Board of Directors,'' said Dr. Chandra Panchal, President and CEO of Procyon. ''Mr. Youman's pharmaceutical experience and strategic thinking will be invaluable as our Company develops a portfolio of innovative products for the treatment and diagnosis of cancer. He brings a wealth of experience in marketing that will assist us as we implement the strategies to finalize the out-licensing opportunities provided by our two late stage products, FIBROSTAT(TM) and COLOPATH(TM). In addition, I also look forward to his strategic perspective as we evaluate the commercial opportunities available to us from the development of our platform technologies.'' Mr. Youmans has over 25 years experience in the international pharmaceutical industry. Prior to his executive role with Novartis, Mr. Youmans was President, International Marketing and Country Operations with Sandoz Pharma AG and President and Chief Operating Officer of Ranbaxy Pharmaceuticals Inc. Previously he held various positions with Glaxo Incorporated including Vice President of Business Planning, Vice President, New Product Market Planning and Vice President, Marketing. He also spent eight years with Eli Lilly and Company during which time he assumed increasing responsibilities in sales and marketing. Procyon BioPharma is a biopharmaceutical company engaged in the discovery and development of innovative products for the treatment and diagnosis of cancer. Procyon BioPharma is advancing a broad pipeline of products based on its proprietary Antinuclear Autoantibody (ANA) and Prostate Secretory Protein (PSP(94)) technologies. The Company has two products in late-stage development, COLOPATH(TM), a rapid, point-of-care screening test for colorectal cancer, and FIBROSTAT(TM), a topical therapeutic cream designed for the management of excessive scars following surgery or serious burns. Procyon BioPharma is headquartered in London, Ontario with research facilities in London, Ontario and Boston, Massachusetts. ''The Alberta Stock Exchange has neither approved or disapproved the information contained herein.'' -30- For further information: Dr. Chandra J. Panchal, President & CEO or Douglas S. Alexander, Senior Vice-President, Finance & CFO, Procyon BioPharma Inc., (519) 432-8486; Public Relations: Gretchen L. P. Schweitzer, Feinstein Kean Partners, (617) 577-8110; Investor Relations: Mark Brennan, Linear Capital Corp., (416) 364-2266